Cooperation in the field of vaccine research Sputnik-V announced that the National Institute of Infectious Diseases Lanzaro Spalantsani located in Rome and the National Research Center of Epidemiology and Microbiology N.F. will start in April. Gamale of Moscow.
The announcement was made by the director of the Italian institute, Professor Francesco Vagia, during an international teleconference hosted by the TASS agency on the promotion of the Russian vaccine and prospects for its use in Italy.
Professor Vagia clarified that The cooperation involves the exchange of experts, biological material and clinical trials, which also includes the possibility of vaccinating volunteers in Italy with the Sputnik-V vaccine in order to investigate the increase of its effectiveness and the creation of a “combination” vaccination.
He also said that the principle of using two adenoviruses is interesting in terms of enhancing the effect.
“We are considering re-vaccinating volunteers who participated in the first phase of clinical trials with another vaccine” Vagia said, as broadcast by the Athens News Agency, without specifying which vaccine will be used for the re-vaccination as it is known that his institute is conducting clinical trials with the Italian vaccine Reithera, which is in the second phase of clinical trials.
The Italian institute will also test the effectiveness of the Russian Sputnik-V vaccine against British, Brazilian and South African strains. .
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
